Plasma EIF2C1 cell-free DNA as a novel biomarker for hepatocellular carcinoma diagnosis and risk stratification
Plasma EIF2C1 levels show promise as a complementary diagnostic and risk-stratification biomarker in HCC. Its combination with AFP improves the identification of metastatic disease at diagnosis, potentially aiding initial clinical management.
Authors
- Linlin Xu (ORCID: https://orcid.org/0000-0001-5855-7221)
- H Wang
- Yang Xiao
- Huoying Chen
- Liyan Jiang
- Ning Li
Institutions
- Guilin Medical University (CN)
Publication Details
- Journal
- Clinics and Research in Hepatology and Gastroenterology
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1016/j.clinre.2026.102808
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00